Sort
82,697 grants matching “vaccine development”
SBIR Phase II: A high throughput microfluidic platform to accelerate biomanufacturing transitions in biologics development
$1,186,726Konstantinos Tsioris · Onecyte Biotechnologies, Inc. · · FY2023 · TIP
Monoclonal antibody isolation and characterization
$1,186,568Rosemarie Mason · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Quantifying Cell-Cell Interactions in the Immune System by Trans-Synaptic Labeling
$1,186,500Gabriel D Victora · Rockefeller University · DP1 · FY2018 · AI
Quantifying Cell-Cell Interactions in the Immune System by Trans-Synaptic Labeling
$1,186,500Gabriel D Victora · Rockefeller University · DP1 · FY2022 · AI
Quantifying Cell-Cell Interactions in the Immune System by Trans-Synaptic Labeling
$1,186,500Gabriel D Victora · Rockefeller University · DP1 · FY2019 · AI
Quantifying Cell-Cell Interactions in the Immune System by Trans-Synaptic Labeling
$1,186,500Gabriel D Victora · Rockefeller University · DP1 · FY2020 · AI
Quantifying Cell-Cell Interactions in the Immune System by Trans-Synaptic Labeling
$1,186,500Gabriel D Victora · Rockefeller University · DP1 · FY2021 · AI
Core D: Clinical Research
$1,186,474Ighovwerha Ofotokun · Emory University · P30 · FY2022 · AI
Inter-regional study of transmission, adaptation and pathogenesis of viruses with pandemic potential in Southeast Asia and West/Central Africa
$1,186,205Anavaj Sakuntabhai · Institut Pasteur · U01 · FY2020 · AI
CENTER FOR DEVELOPMENT OF ANTISPERM CONTRACEPTIVES
$1,186,048University Of California Davis · U54 · FY2000 · HD
Chicago Clinical Trials Unit
$1,185,973Babafemi O Taiwo · Northwestern University At Chicago · UM1 · FY2022 · AI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection
$1,185,932Sergei V Kotenko · Rbhs-New Jersey Medical School · R01 · FY2015 · AI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection
$1,185,932Sergei V Kotenko · Rbhs-New Jersey Medical School · R01 · FY2016 · AI
A Global Research Resource for Human Tuberculosis
$1,185,782Adrie Jc Steyn · University Of Alabama At Birmingham · R24 · FY2024 · AI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection
$1,185,617Sergei V Kotenko · Rbhs-New Jersey Medical School · R01 · FY2014 · AI
Effects of genetic polymorphism in MHC, KIR, and related loci on human disease
$1,185,403Mary N. Carrington · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
MATERNAL IMMUNIZATION TO PREVENT INFANT OTITIS MEDIA
$1,185,349University Of Minnesota Twin Cities · R01 · FY2004 · DC
Critical Path Project: Mapp66, a Multi-antibody Prevention Product
$1,185,347Kevin John Whaley · Boston University Medical Campus · U19 · FY2012 · AI
Discovery and Targeting of West Nile Virus Epitopes
$1,185,329William Hildebrand · University Of Oklahoma Hlth Sciences Ctr · U01 · FY2011 · AI
Microarrays and Macaque Influenza Model
$1,185,155Michael G Katze · Icahn School Of Medicine At Mount Sinai · P01 · FY2007 · AI
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure
$1,184,950Sharon Riddler · University Of Pittsburgh At Pittsburgh · U01 · FY2021 · AI
PEDIATRIC ACTG--ACTU
$1,184,741Children'S Hospital Boston · U01 · FY2001 · AI
SASEA
$1,184,630Rebecca Kathleen Fielding-Miller · University Of California, San Diego · U01 · FY2023 · HD
Targeting CD180 to induce anti-KSHV response in nonhuman primates
$1,184,569Scott W Wong · Oregon Health & Science University · U01 · FY2025 · CA
Cornell Clinical Trials Unit
$1,184,443Roy M Gulick · Weill Medical Coll Of Cornell Univ · U01 · FY2008 · AI